Prana Announces Results of REACH2HD Huntington Disease Trial

The long awaited clinical trial results for the REACH2HD study run by the Huntington Study Group for Prana Biotechnology were announced today.  The REACH2HD study assessed the safety and tolerability of 2 doses (100 and 250mg) of Prana’s investigational drug, PBT2 over the course of 26 weeks.  PBT2 is a compound that is thought to act by binding metals commonly found in the body, such as copper and iron, and redistributing them to where they are needed.  For example, the redistribution of copper has been shown in cellular and animal models of HD and Alzheimer’s disease to reduce toxic protein accumulation.

PBT2 appeared to be both safe and tolerable to the small group of 74 study participants that received the drug.  In addition, they report a statistically significant improvement in one of their eight secondary efficacy tests called the Trail Making Test Part B.  This test requires subjects to connect numbers to letters with a line (1, A, 2, B, 3, C…) as quickly as possible.  The test is commonly used to examine executive functioning and mental flexibility in people. The safety, significant improvement in the Trail Making Test and encouraging pilot data using brain imaging as a readout have prompted Prana to announce they will advance PBT2 into a larger Phase 3 clinical trial for HD soon.

For more information on the REACH2HD study please see the Prana press release here.